RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for the treatment of Coronary Artery Disease (CAD). CAD is a leading global cause of morbidity and mortality, primarily driven by the formation of atherosclerotic plaques and associated thrombotic complications, such as myocardial infarction and other ischemic events. Despite the widespread use of standard therapies, including antiplatelet and anticoagulant treatments, patients with stable CAD continue to face a significant residual risk of thrombotic events even under optimized care. Current treatments are further limited by an increased risk of bleeding, which restricts their therapeutic intensity and long-term dosing regimens in many patients. RBD1119 injection represents a novel anti-thrombotic siRNA therapy designed to provide effective and durable protection against thrombosis while maintaining a favorable safety profile, particularly regarding bleeding risk.